Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors

J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O'Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. BensonR. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M.L. Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, E. Krenning, Stefano Severi

Research output: Contribution to journalArticle

Original languageItalian
Pages (from-to)125-135
Number of pages11
JournalNew England Journal of Medicine
Volume376
Issue number2
DOIs
Publication statusPublished - 2017

Cite this

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., ... Severi, S. (2017). Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors. New England Journal of Medicine, 376(2), 125-135. https://doi.org/10.1056/NEJMoa1607427